Aptevo Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
APVO Nasdaq 2830 aptevotherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aptevo Therapeutics Inc.

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone - Jul 27th, 2026 6:05 am
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - Jun 30th, 2026 6:05 am
APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement - Jun 16th, 2026 3:15 am
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer - May 28th, 2026 6:05 am
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing - May 27th, 2026 6:05 am
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy - May 20th, 2026 10:00 am
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - May 13th, 2026 6:05 am
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - May 6th, 2026 6:05 am
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why - Apr 10th, 2026 10:00 am
Aptevo to Participate in March 2026 Conferences - Mar 19th, 2026 6:05 am
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% - Mar 10th, 2026 6:05 am
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth - Feb 3rd, 2026 6:05 am
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality - Jan 9th, 2026 6:05 am
Sector Update: Health Care Stocks Edge Higher Late Afternoon - Dec 26th, 2025 2:06 pm
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split - Dec 26th, 2025 6:05 am
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 - Dec 9th, 2025 6:05 am
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nov 19th, 2025 7:55 am
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors - Nov 10th, 2025 6:05 am
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update - Nov 6th, 2025 6:05 am
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter - Oct 8th, 2025 6:20 am